PeptideStack
5.2kquestions
20kanswers
220users

How do I compute the +5 charge state m/z for a peptide of 4113.6 Da?

Asked 1 Aug 2024Modified 22 months agoViewed 35k times
31

Conditions: +5 · 4113.6 Da.

I want the working, not the result — I need to be able to redo it with different numbers.

I care about the precision as well as the value — I want to know how many figures are real.

Where is my error, and what is the correct working?

mass-spec
mass-spec

Mass spectrometry for identity confirmation: electrospray ionisation, multiple charge states, monoisotopic versus average mass, deconvolution, and…

38 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

811 questions
purity
purity

Purity as chromatographic area per cent - the fraction of detected material that is your target peak. It says nothing about how much material is…

788 questions
shareeditfollowflag
WO
askedw_okoye40k1381 Aug 2024

5 Answers

Accepted answer first, then by votes
119

Accepted answer

The single most important fact about mass spectrometry for peptides is that it measures only the molecular weight and tells you almost nothing about whether the peak is actually your target.

The charge state distribution depends on the solution pH, the structure of the peptide and the source conditions, so the same peptide can look different under different conditions.

The m/z accuracy achievable depends on the mass analyser type — quadrupole gives low accuracy, time-of-flight gives moderate accuracy, and Orbitrap gives high accuracy.

Peptide mapping — enzymatic digestion followed by tandem mass spectrometry — can confirm the primary sequence and is the method of choice when identity is ambiguous.

A correct mass is necessary for identity but not sufficient — you also need the chromatography to confirm it.

shareimprove this answerflag
DV
answered · accepteddead_volume49k3812 Oct 2024
5Worth adding that the method section is where the answer usually is. – tobias_maartens 8 months ago
add a comment
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results
52

Specifically, identity confirmation from mass spectrometry means matching the observed m/z to the calculated m/z for your peptide at its known charge states.

High-resolution mass spectrometry can distinguish a Lys-containing peptide from an Arg-containing peptide of similar mass because of the isotope difference.

A mass shift of plus sixteen usually means oxidation at methionine or tryptophan, which is common in peptides and often comes from sample handling rather than synthesis failure.

Electrospray ionisation soft-ionisation behaviour is well-characterised and standards exist for m/z calibration and mass accuracy assessment.

Always run a blank between samples and check for carry-over.

shareimprove this answerflag
M4
answeredmz_411399k2589 Sept 2024
2I have seen exactly this failure mode twice and both times it was the diluent. – net_peptide 5 months ago
The distinction between purity and content cannot be repeated often enough here. – vialroom 3 months ago
add a comment
41

On the detail: two ions with the same nominal mass but different molecular formulae have different exact masses, and only high-resolution mass spectrometry can distinguish them.

A mass shift of minus one hundred and twenty-eight usually means a missing Gln or Lys residue from a synthesis deletion sequence.

A mass shift of plus one usually means deamidation at asparagine or glutamine, which creates a secondary amine instead of an amide and changes the mass by exactly one.

Worth noting that source contamination is common and silent, so a result that looks too good to be true often is.

The practical summary: use mass spectrometry for identity, not for purity.

shareimprove this answerflag
HV
answeredh_villanueva50k3820 Sept 2024
4

Put another way, coupling HPLC to a mass spectrometer adds identity information to the chromatographic separation, but the mass spectrometer's ionisation conditions can distort the HPLC peak shape.

The baseline noise on a mass spectrum sets the limit of detection, and a weak signal close to the noise is not reliable evidence for the presence of a species.

False positives from contamination are common in mass spectrometry work, and running a blank between every sample and a solvent background are standard practice.

The limitation is that mass spectrometry tells you the mass and almost nothing else, so it needs to be paired with chromatography or other identity information.

A correct mass is necessary for identity but not sufficient — you also need the chromatography to confirm it.

edited 16 Sept 2024 by lane_transit — added the method parameters

shareimprove this answerflag
LT
answeredlane_transit42k3818 Aug 2024
This should probably be in the site help pages rather than buried in an answer. – Dr_Colm_Fitzhenry 3 months ago
8Good answer, but the confidence interval in the cited trial is wider than implied. – t_oyelaran 38 days ago
add a comment
2

The limit of detection in electrospray is orders of magnitude better than in HPLC, which means a mass spectrometer can see species that the chromatograph cannot.

Electrospray ionisation creates multiple charge states of the same peptide — a 4 kDa peptide might appear at +2, +3 and +4 — and all of them must be accounted for in the spectrum.

Peptide mapping — enzymatic digestion followed by tandem mass spectrometry — can confirm the primary sequence and is the method of choice when identity is ambiguous.

I would not trust a mass result without a good baseline and a blank injection check.

Always run a blank between samples and check for carry-over.

shareimprove this answerflag
SS
answeredswirl_dont_shake19k281 Oct 2024

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.